Ellen Chiniara

Directeur Juridique

Alexion Pharmaceuticals, Inc.Alexion Pharmaceuticals, Inc.Kymera Therapeutics, Inc.

Insider activity · 24 months0 buys1 saleCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 1 saleFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (0 ops.)

—

▼ Sales (2 ops.)

€195k

Latest filing published 03 Mar 2025 for Kymera Therapeutics, Inc.. Read the official filing

Filing timeline

BuySale

Ellen Chiniara

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

Ellen Chiniara: trading record in brief

Ellen Chiniara, listed as senior executive, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Kymera Therapeutics, Inc. and Alexion Pharmaceuticals Inc. We count 7 filings; the first trade dates from 14 July 2021 and the latest from 3 March 2025.

No open-market purchase appears, only 2 sales worth €195k. Other entries cover 4 share grants. So far in 2025, the count stands at no purchases and 1 sale.

On 3 March 2025 came the latest disclosure, a share grant in Kymera Therapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.